Resource Summary Report

Generated by dkNET on Aug 20, 2026

HepAD38

RRID:CVCL_M177
Type: Cell Line

Proper Citation

RRID:CVCL_M177

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_M177

Proper Citation: RRID:CVCL_M177

Description: Cell line HepAD38 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hepatoblastoma

Defining Citation: PMID:9257747, PMID:9875378, PMID:21331898

Comments: Virology: Inducibly expresses a hepatitis B virus (HBV) genome under the control of a tet operator/CMV promoter. Upon removal of tetracycline the cell line produces viral RNA and secrete virus-like particles into the supernatant., Biotechnology: Used in a bioassay that permits the large-scale screening of compound libraries for inhibitors of HBV replication., Population: Caucasian., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HepAD38

Synonyms: Hep AD38, HepG2 AD38, HepG2-AD38, Hep G2 AD 38, AD-38, AD38

Cross References: BTO:BTO_0006298, ATCC:CRL-3561, ATCC:CRL-12077, cancercelllines:CVCL_M177, Wikidata:Q54882829

ID: CVCL_M177

Hierarchy: cvcl_0027

Record Creation Time: 20220427T220335+0000

Record Last Update: 20260815T233735+0000

Ratings and Alerts

No rating or validation information has been found for HepAD38.

Warning: Discontinued: ATCC; CRL-12077
Virology: Inducibly expresses a hepatitis B virus (HBV) genome under the control of a tet operator/CMV promoter. Upon removal of tetracycline the cell line produces viral RNA and secrete virus-like particles into the supernatant., Biotechnology: Used in a bioassay that permits the large-scale screening of compound libraries for inhibitors of HBV replication., Population: Caucasian., Group: Patented cell line.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 245 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Li C, et al. (2026) Scavenger receptor class F member 2 is an intracellular receptor for hepatitis B virus. Cell, 189(14), 4454.

Zhang R, et al. (2026) TRMT6-Mediated m1A Modification of CDK9 mRNA is a Dual-Pronged Pathogenic Driver for HBV-Related Hepatocellular Carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(39), e14172.

Chen L, et al. (2025) A Galactose-Engineered Dual-Responsive Nanocarrier for ASO/CRISPR-Cas9 Delivery to Inhibit HBV Replication. Advanced healthcare materials, e02835.

Shi Y, et al. (2023) Release of hepatitis B virions is positively regulated by glucose-regulated protein 78 through direct interaction with preS1. Journal of medical virology, 95(1), e28271.

Li YY, et al. (2023) Hepatitis B Virus Utilizes a Retrograde Trafficking Route via the Trans-Golgi Network to Avoid Lysosomal Degradation. Cellular and molecular gastroenterology and hepatology, 15(3), 533.

Saeed U, et al. (2023) PIN1 and PIN4 inhibition via parvulin impeders Juglone, PiB, ATRA, 6,7,4'-THIF, KPT6566, and EGCG thwarted hepatitis B virus replication. Frontiers in microbiology, 14, 921653.

Yang Y, et al. (2023) O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. Signal transduction

and targeted therapy, 8(1), 63.

Legrand AF, et al. (2023) Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity. Hepatology communications, 7(5).

Hofmann S, et al. (2023) SUMO Modification of Hepatitis B Virus Core Mediates Nuclear Entry, Promyelocytic Leukemia Nuclear Body Association, and Efficient Formation of Covalently Closed Circular DNA. Microbiology spectrum, 11(3), e0044623.

Zheng Y, et al. (2023) Hepatitis B virus hijacks TSG101 to facilitate egress via multiple vesicle bodies. PLoS pathogens, 19(5), e1011382.

Cai J, et al. (2023) Plerixafor and resatorvid inhibit hepatitis B virus in vitro by upregulating elongation factor Tu GTP-binding domain containing 2. Frontiers in cellular and infection microbiology, 13, 1118801.

Xie C, et al. (2023) Lnc-AIFM2-1 promotes HBV immune escape by acting as a ceRNA for miR-330-3p to regulate CD244 expression. Frontiers in immunology, 14, 1121795.

Jabeen K, et al. (2023) Restoration of IL-11 and IL-15 cytokine production post calcium modulators and ROS treatment can assist viral clearance both in vitro and in vivo. Iranian journal of basic medical sciences, 26(2), 176.

Zuo D, et al. (2023) A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo. Protein & cell, 14(1), 37.

Burm R, et al. (2023) Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections. Gut, 72(6), 1186.

Chen J, et al. (2023) A functional variant of CD40 modulates clearance of hepatitis B virus in hepatocytes via regulation of the ANXA2/CD40/BST2 axis. Human molecular genetics, 32(8), 1334.

Wang Y, et al. (2023) HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression. Cancer research, 83(7), 1048.

Yuan S, et al. (2023) HBV X Protein Induces Degradation of UBXN7, a Novel Negative Regulator of NF-??B Signaling, to Promote HBV Replication. Cellular and molecular gastroenterology and hepatology, 15(1), 179.

Liu Y, et al. (2023) Apolipoprotein H induces sex-specific steatohepatitis and gut dysbiosis during chronic hepatitis B infection. iScience, 26(3), 106100.

Burdette D, et al. (2023) Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection. Antimicrobial agents and chemotherapy, 67(1), e0134822.